ClinicalTrials.gov
ClinicalTrials.gov Menu

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00618332
Recruitment Status : Completed
First Posted : February 20, 2008
Results First Posted : January 10, 2014
Last Update Posted : February 14, 2014
Sponsor:
Collaborator:
Schering-Plough
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.

Condition or disease Intervention/treatment Phase
Seasonal Allergic Rhinitis Drug: mometasone furoate nasal spray Drug: placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?
Study Start Date : April 2008
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2010


Arm Intervention/treatment
Active Comparator: 1
2 weeks of treatment
Drug: mometasone furoate nasal spray
2 puffs in each nostril once a day for 2 weeks
Other Name: Nasonex

Placebo Comparator: 2
2 weeks of treatment
Drug: placebo
2 puffs in each nostril once a day for 2 weeks
Other Name: placebo comparator for Nasonex




Primary Outcome Measures :
  1. Global Assessment [ Time Frame: at week 2 ]

    Global Assessment: 3=significantly improved, 2=moderately improved,

    1=mildly improved, 0=no change, -1=mildly worse, -2=moderately worse, and -3=significantly worse



Secondary Outcome Measures :
  1. Changes in RQLQ: Overall [ Time Frame: Baseline and 2 weeks ]
    The RQLQ is a disease-specific measure of a patient's quality of life. It includes domains that measure nasal and eye symptoms as well as those of activity, sleep, non-nasal/eye symptoms, practical and emotional measures. A scale of 0-6 is used to record the patient responses, with lower scores reflecting a better quality of life. The average score of each domain is calculated as well as an overall domain score reflecting the average of all scores.

  2. Changes in RQLQ: Activity [ Time Frame: Baseline and 2 weeks ]
    The RQLQ activity range: 0-6. Higher scores indicate a worse quality of life.

  3. Changes in RQLQ: Sleep [ Time Frame: Baseline and 2 weeks ]
    The RQLQ sleep range: 0-6. Higher scores indicate a worse quality of life.

  4. Changes in RQLQ: Non-Nasal/Eye [ Time Frame: Baseline and 2 weeks ]
    The RQLQ non-nasal/eye range: 0-6. Higher scores indicate a worse quality of life.

  5. Changes in RQLQ: Practical [ Time Frame: Baseline and 2 weeks ]
    The RQLQ practical range: 0-6. Higher scores indicate a worse quality of life.

  6. Changes in RQLQ: Nasal [ Time Frame: Baseline and 2 weeks ]
    The RQLQ nasal range: 0-6. Higher scores indicate a worse quality of life.

  7. Changes in RQLQ: Emotional [ Time Frame: Baseline and 2 weeks ]
    The RQLQ emotional range: 0-6. Higher scores indicate a worse quality of life.

  8. Changes in RQLQ: Eye [ Time Frame: Baseline and 2 weeks ]
    The RQLQ eye range: 0-6. Higher scores indicate a worse quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Males and females between 18 and 60 years of age.
  2. History of grass and/or ragweed allergic rhinitis.
  3. Positive skin or RAST test to grass, trees and/or ragweed antigen.
  4. Symptomatic at time of entry into study.

Exclusion Criteria

  1. Women of childbearing potential not using the contraception method(s) (Birth control pills, depo Provera, double barrier) as well as women who are pregnant or breastfeeding.
  2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).
  3. Use of any other investigational agent in the last 30 days.
  4. Absence of nasal symptoms.
  5. Smoking.
  6. URI at the time of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00618332


Locations
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Schering-Plough
Investigators
Principal Investigator: Robert M Naclerio, MD University of Chicago

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT00618332     History of Changes
Other Study ID Numbers: 15624B
First Posted: February 20, 2008    Key Record Dates
Results First Posted: January 10, 2014
Last Update Posted: February 14, 2014
Last Verified: January 2014

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Mometasone Furoate
Nasal Decongestants
Pseudoephedrine
Ephedrine
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents
Vasoconstrictor Agents
Respiratory System Agents
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Anti-Asthmatic Agents